Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...

Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain generic medications to skyrocket.

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state ...

Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Any differences are carefully ...

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.24 which represents a decrease of $-0.06 or -0.28% from the prior close of $21.3. The stock opened at $21.4 and ...

Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...